clb-8k_successionplan.htm

 
UNITED STATES
 
 
SECURITIES AND EXCHANGE COMMISSION
 
 
Washington, D.C. 20549
 
 
________________
 
 
FORM 8-K
 
 
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of report (date of earliest event reported): March 2, 2011
 
 
  
 
 
CORE LABORATORIES N.V.
 
 
(Exact name of registrant as specified in its charter)
 
 
001-14273
 
 
(Commission File Number)
 
The Netherlands
Not Applicable
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
   
Herengracht 424
  
1017 BZ Amsterdam
  
The Netherlands
Not Applicable
(Address of principal executive offices)
(Zip Code)
   
 
Registrant's telephone number, including area code: (31-20) 420-3191
 
 
 
 
 
Check the appropriate below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
   
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

 
 
 

 
Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
 
 
On March 2, 2011, the Supervisory Board of Directors of Core Laboratories N.V. approved a Board Succession Plan.  The approved plan is set forth in Exhibit 99.1 attached hereto.
 
 
Item 9.01 Financial Statements and Exhibits
 
 
(d)
  
Exhibits
 
99.1  
Board Succession Plan, dated March 2, 2011  *
 
 
* This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Exchange Act.
 
 

 
 

 

 
 
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
             
   
Core Laboratories N.V.
             
Dated: March 7, 2011
  
By
  
/s/ Richard L. Bergmark
    
       
Richard L. Bergmark
    
       
Chief Financial Officer
    
 
 
 
 
 
 
 
 
 

 
 
 

 
CORE LABORATORIES N.V.
 
 
EXHIBIT INDEX TO FORM 8-K
 
 
 
 
 
 
 
 
 
 
     
EXHIBIT NO.
  
ITEM
     
99.1
  
Board Succession Plan, dated March 2, 2011 *
 
 * This exhibit is intended to be furnished and shall not be deemed "filed" for purposes of the Exchange Act.